表纸
市场调查报告书

新型冠状病毒感染疾病 (COVID-19) 诊断药、治疗药的全球市场 (~2025年):PCR检验、抗体检验、免疫治疗药、疫苗、抗病毒药物、细胞治疗药、血浆治疗药

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

出版商 Meticulous Market Research Pvt. Ltd. 商品编码 946876
出版日期 内容资讯 英文 100 Pages
订单完成后即时交付
价格
新型冠状病毒感染疾病 (COVID-19) 诊断药、治疗药的全球市场 (~2025年):PCR检验、抗体检验、免疫治疗药、疫苗、抗病毒药物、细胞治疗药、血浆治疗药 COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025
出版日期: 2020年07月03日内容资讯: 英文 100 Pages
简介

世界各国的卫生署及医疗研究人员,以新型冠状病毒感染疾病 (COVID-19)的感染扩大防止为目标,竞争摸索著解决方案。开发中的治疗药的50%以上虽然依然在前临床阶段,但是由于FDA的紧急使用许可 (EUA) 等努力,预期R&D流程加速。预计COVID-19诊断药、治疗药的市场机会,2025年达到139亿美元的规模。其中疫苗及抗病毒药物,全球的研究人员现在也最大量地研究。

本报告提供全球新型冠状病毒感染疾病 (COVID-19) 诊断药、治疗药的市场调查,市场定义和概要,COVID-19概要、现状,COVID-19诊断药、治疗药的开发平台趋势,各地区的影响与开发的措施,主要企业的配合措施等汇整资料。

第1章 简介

第2章 调查手法

第3章 冠状病毒:流行病学

第4章 摘要整理

  • 简介
  • 世界经济的影响
  • COVID-19的应对
  • COVID-19:研究开发平台
  • COVID-19开发平台上的课题
  • 主要企业

第5章 Covid-19:医疗部门的影响

  • 简介
  • 主要趋势、详细部门的影响
  • 诊断药
    • PCR、迅速抗原检验、核酸为基础的检验
    • 抗体检验、血清检验
  • 治疗药
    • 疫苗
    • 免疫疗法(抗体)
    • 抗病毒药物
    • 细胞为基础的治疗药
    • 其他

第6章 影响分析:各地区

  • 简介
  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区

第7章 竞争情形

  • 简介
  • 契约、交易、联盟、合作、JV
  • R&D最新趋势
  • 认证、核准
  • 捐献
  • 投入资金
  • 生产能力的扩大
  • 其他成长策略

第8章 企业的最新趋势

  • 企业区分
  • 诊断药
    • Roche Holding Ag
    • Thermo Fisher Scientific, Inc.
    • Becton, Dickinson and Company
    • Abbott Laboratories
    • Cepheid (Subsidiary of Danaher Corporation)
  • 抗病毒药物
    • Abbivie Corporation
    • Gilead Sciences, Inc.
    • Eli Lilly And Company
  • 疫苗开发
    • Moderna, Inc.
    • Novavax, Inc
    • Medicago, Inc
    • Inovio Pharmaceuticals, Inc.
    • GlaxoSmithKline (GSK)
    • Sanofi S.A.
    • Johnson & Johnson
  • 免疫治疗
    • Sorrento Therapeutics, Inc.
    • Astrazeneca Plc
    • Pfizer, Inc.
    • Cti Biopharma Corporation
    • Oncoimmune, Inc.
  • 细胞治疗
    • Athersys,Inc.
    • Cellularity,Inc.
    • Pluristem Therapeutics,Inc.
  • 血浆疗法
    • Takeda Pharmaceutical Company Ltd
目录

The healthcare systems have been struggling to manage the COVID-19 patient population globally and hence the medical researchers are racing to find a solution to the pandemic. According to this latest publication from Meticulous Research®, the leading areas of research include antibodies, protein-based vaccines, antiviral, drug repurposes, RNA-based vaccines, non-replicating viral vectors, and cell-based therapies. While more than 50% of the therapies being developed are in preclinical stage, government initiatives, such as Emergency Use Authorization (EUA) by FDA, is expected to accelerate the research and development (R&D) process.

Based on healthcare options, the COVID-19 impact assessment is analyzed into diagnostics and treatments areas. The market opportunity of these products is estimated to reach USD 13.9 billion in 2025. The diagnostics segment is further divided into PCR-based testing and antibody testing. The treatment area is segmented into vaccines, immunotherapies, anti-virals, cell-based therapies, and other therapies. Vaccines and anti-virals are the most explored treatment options currently being investigated by researchers worldwide.

Geographically, North America has been the most affected region, primarily attributed to the U.S. being the most affected country having most number of confirmed cases as well as deaths, globally. Other most affected nations include the U.K., Spain, France, Italy, Brazil, Germany, and India among others. Further, almost all the affected nations have experienced rapid economic decline leading GDP decline, increase in unemployment rates, and increase in the inflation rates. To overcome the situation, governments have imposed restriction on people movement as well as invested resources towards dealing with crisis and supporting all research and medical efforts towards developing a treatment option. The U.S., Canada, the U.K., Germany, China, and India are some of the key nations leading the research and production efforts geared towards developing COVID-19 medication.

Some of the key players engaged in COVID-19 diagnostics and treatment development include: Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), and Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline

  • Diagnosis
    • PCR Testing
    • Antibody Testing
  • Treatment
    • Vaccines
    • Immunotherapy
    • Antiviral
    • Cell-based Therapy
    • Other Therapies

COVID-19: Impact on Healthcare Industry

  • Diagnostics
    • Rapid Test Kits
    • PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
  • Advantages Offered by PCR Testing in COVID -19 Diagnosis
  • Restraints
  • Key Companies
    • Antibody Testing / Serological Testing
  • Advantages Over Molecular Tests
  • Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
  • Restraints
  • Key Companies
    • Therapies
  • Vaccines
  • Immunotherapies (Antibodies)
  • Monoclonal Antibody
  • T-Cell Therapy
  • Potential Game Changers: Antibodies
  • Ilaris (Canakinumab)
  • Sylvant (Siltuximab)
  • Lenzilumab
  • Ultomiris (Ravulizumab-Cwvz)
  • Tocilizumab
  • Anti-Virals
  • Potential Game Changers
  • Chloroquine and Hydroxychloroquine (HCQ)
  • Remdesivir
  • Cell-Based Therapies
  • Other Therapies
  • Plasma Therapy
  • Devices

COVID-19 Industry Impact Assessment, by Geography

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World (RoW)

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Markets Covered
  • 1.3. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Key Stakeholders

2. Research Methodology

  • 2.1. Research Methodology Steps
  • 2.2. Secondary and Primary Research Methodology
    • 2.2.1. Secondary Research
      • 2.2.1.1. Key Data from Secondary Sources
    • 2.2.2. Primary Research
      • 2.2.2.1. Key Data from Primary Sources
      • 2.2.2.2. Key Insights from Primary Sources
  • 2.3. Market Size Estimation Methodology
  • 2.4. Market Forecast Methodology
  • 2.5. Market Breakdown and Data Triangulation

3. Coronavirus: Epidemiology

  • 3.1. About Coronavirus
  • 3.2. Transmission & Symptoms
  • 3.3. Prevention
  • 3.4. Epidemiology

4. Executive Summary

  • 4.1. Introduction
  • 4.2. Global Economic Impact
  • 4.3. COVID-19 Response
  • 4.4. COVID-19 Research Pipeline
  • 4.5. COVID-19 Pipeline Development Challenges
  • 4.6. Key Companies

5. Covid-19: Impact on Healthcare Industry

  • 5.1. Introduction
  • 5.2. Key Trends & Impact on Healthcare Subsegments
  • 5.3. Diagnostics
    • 5.3.1. PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
      • 5.3.1.1. Advantages Offered by PCR Testing in COVID -19 Diagnosis
      • 5.3.1.2. Restraints
      • 5.3.1.3. Key Companies
    • 5.3.2. Antibody Testing / Serological Testing
      • 5.3.2.1. Advantages Over Molecular Tests
      • 5.3.2.2. Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
      • 5.3.2.3. Restraints
      • 5.3.2.4. Key Companies
  • 5.4. Therapies
    • 5.4.1. Vaccines
    • 5.4.2. Immunotherapies (Antibodies)
      • 5.4.2.1. Monoclonal Antibody
      • 5.4.2.2. T-Cell Therapy
      • 5.4.2.3. Potential Game Changers: Antibodies
        • 5.4.2.3.1. Ilaris (Canakinumab)
        • 5.4.2.3.2. Sylvan (Siltuximab)
        • 5.4.2.3.3. Lenzilumab
        • 5.4.2.3.4. Ultomiris (Ravulizumab-CWVZ)
        • 5.4.2.3.5. Tocilizumab
    • 5.4.3. Antivirals
      • 5.4.3.1. Potential Game Changers
        • 5.4.3.1.1. Chloroquine and Hydroxychloroquine (HCQ)
        • 5.4.3.1.2. Remdesivir
    • 5.4.4. Cell-Based Therapies
    • 5.4.5. Other Therapies
      • 5.4.5.1. Plasma Therapy
      • 5.4.5.2. Devices

6. Geography Impact Assessment

  • 6.1. Introduction
    • 6.1.1. Global Virtual Fund-Raising Event to Raise USD 8 Billion for Coronavirus Vaccine
  • 6.2. North America
    • 6.2.1. COVID-19 Impact on the U.S. Economy
    • 6.2.2. Significant R&D Investment by the U.S. Government for COVID-19 Treatment
    • 6.2.3. High Dependence on the U.S. on Drugs Import Expected to Create Drug Shortages
    • 6.2.4. Investments by Coalition for Epidemic Preparedness Innovations (CEPI) and Canadian Government
    • 6.2.5. Canada Announced Investment of USD 192 Million on Vaccine Development as Well as Partnering with Industry and Academics
    • 6.2.6. Creation of SARS-COV2 Vaccine-Bank by Researchers in Canada
  • 6.3. Europe
    • 6.3.1. Economic Impact of COVID-19: European Nations
    • 6.3.2. European Firms to Lead the COVID-19 Treatment Researches
    • 6.3.3. U.K. at Forefront in Drug Development Researches to Fight Covid-19
    • 6.3.4. Partnership of European Pharmaceutical Giants - Sanofi and GSK To Develop COVID-19 Vaccine
    • 6.3.5. German Vaccine Became the First European MRNA Vaccine to Enter Human Testing
    • 6.3.6. Growing Interest of Billionaire in German Drug Development for COVID-19
  • 6.4. APAC
    • 6.4.1. Economic Impact of COVID-19: APAC
    • 6.4.2. Asian Countries Leading the Diagnostics Test Commercialization
    • 6.4.3. India In Favourable Position for Future Production Of COVID-19 Vaccine
    • 6.4.4. Chinese Lockdown to Negatively Impact the Drugs Supply Chain
  • 6.5. Rest of the World
    • 6.5.1. Government Initiatives to Support COVID-19 Medicine Research & Other Drug Supply in Brazil
    • 6.5.2. Saudi Arabia to Invest USD 2 Billion in Coronavirus Vaccine Development
    • 6.5.3. Government Initiatives to Support Rapid Development of COVID-19 Therapy in South Africa

7. Competitive Landscape

  • 7.1. Introduction
  • 7.2. Agreements/Deals/Partnerships/Collaborations/Joint Ventures
  • 7.3. R&D Updates
  • 7.4. Auhrozation / Approvals
  • 7.5. Donations Made
  • 7.6. Funding Received
  • 7.7. Capacity Expansion
  • 7.8. Other Growth Strategies

8. Company Updates

  • 8.1. Company Segmentation
  • 8.2. Diagnostic Companies
    • 8.2.1. Roche Holding Ag
      • 8.2.1.1. About the Firm
      • 8.2.1.2. COVID-19 Pipeline
      • 8.2.1.3. Recent Developments
    • 8.2.2. Thermo Fisher Scientific, Inc.
      • 8.2.2.1. About the Firm
      • 8.2.2.2. COVID-19 Pipeline
      • 8.2.2.3. Recent Developments
    • 8.2.3. Becton, Dickinson and Company
      • 8.2.3.1. About the Firm86
      • 8.2.3.2. COVID-19 Pipeline
      • 8.2.3.3. Recent Developments
    • 8.2.4. Abbott Laboratories
      • 8.2.4.1. About the Firm
      • 8.2.4.2. COVID-19 Pipeline
      • 8.2.4.3. Recent Developments
    • 8.2.5. Cepheid (Subsidiary of Danaher Corporation)
      • 8.2.5.1. About the Firm
      • 8.2.5.2. COVID-19 Pipeline
      • 8.2.5.3. Recent Developments
  • 8.3. Antivirals
    • 8.3.1. Abbivie Corporation
      • 8.3.1.1. About the Firm
      • 8.3.1.2. COVID-19 Pipeline
      • 8.3.1.3. Recent Developments
    • 8.3.2. Gilead Sciences, Inc.
      • 8.3.2.1. About the Firm
      • 8.3.2.2. Covid-19- Pipeline
      • 8.3.2.3. Recent Developments
    • 8.3.3. Eli Lilly And Company
      • 8.3.3.1. About the Firm
      • 8.3.3.2. Covid-19- Products
      • 8.3.3.3. Recent Developments
  • 8.4. Vaccine Developers
    • 8.4.1. Moderna, Inc.
      • 8.4.1.1. About the Firm
      • 8.4.1.2. COVID-19 Pipeline
      • 8.4.1.3. Recent Developments
    • 8.4.2. Novavax, Inc
      • 8.4.2.1. About the Firm
      • 8.4.2.2. COVID-19 Pipeline
      • 8.4.2.3. Recent Developments
    • 8.4.3. Medicago, Inc
      • 8.4.3.1. About the Firm
      • 8.4.3.2. COVID-19 Pipeline
      • 8.4.3.3. Recent Developments
    • 8.4.4. Inovio Pharmaceuticals, Inc.
      • 8.4.4.1. About the Firm
      • 8.4.4.2. COVID-19 Pipeline
      • 8.4.4.3. Recent Developments
    • 8.4.5. GlaxoSmithKline (GSK)
      • 8.4.5.1. About the Firm
      • 8.4.5.2. COVID-19 Pipeline
      • 8.4.5.3. Recent Developments
    • 8.4.6. Sanofi S.A.
      • 8.4.6.1. About the Firm
      • 8.4.6.2. COVID-19 Pipeline
      • 8.4.6.3. Recent Developments
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. About the Firm
      • 8.4.7.2. COVID-19 Pipeline
      • 8.4.7.3. Recent Developments
  • 8.5. Immunotherapy Firms
    • 8.5.1. Sorrento Therapeutics, Inc.
      • 8.5.1.1. About the Firm
      • 8.5.1.2. COVID-19 Pipeline
      • 8.5.1.3. Recent Developments
    • 8.5.2. Astrazeneca Plc
      • 8.5.2.1. About the Firm
      • 8.5.2.2. COVID-19 Pipeline
      • 8.5.2.3. Recent Developments
    • 8.5.3. Pfizer, Inc.
      • 8.5.3.1. About the Firm
      • 8.5.3.2. COVID-19 Pipeline
      • 8.5.3.3. Recent Developments
    • 8.5.4. Cti Biopharma Corporation
      • 8.5.4.1. About the Firm
      • 8.5.4.2. COVID-19 Pipeline
      • 8.5.4.3. Recent Developments
    • 8.5.5. Oncoimmune, Inc.
      • 8.5.5.1. About the Firm
      • 8.5.5.2. COVID-19 Pipeline
      • 8.5.5.3. Recent Developments
  • 8.6. Cell-Based Therapy
    • 8.6.1. Athersys, Inc.
      • 8.6.1.1. About the Firm
      • 8.6.1.2. COVID-19 Pipeline
      • 8.6.1.3. Recent Developments
    • 8.6.2. Cellularity, Inc.
      • 8.6.2.1. About the Firm
      • 8.6.2.2. COVID-19 Pipeline
      • 8.6.2.3. Recent Developments
    • 8.6.3. Pluristem Therapeutics, Inc.
      • 8.6.3.1. About the Firm
      • 8.6.3.2. COVID-19 Pipeline
      • 8.6.3.3. Recent Developments
  • 8.7. Plasma Therapy
    • 8.7.1. Takeda Pharmaceutical Company Ltd
      • 8.7.1.1. About the Firm
      • 8.7.1.2. COVID-19 Pipeline
      • 8.7.1.3. Recent Developments

List of Tables

  • Table 1 Health & Life Sciences Market Opportunity Assessment Post COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 2 Industry Trend & Impact Analysis on Healthcare Sub-Sectors Post COVID-19
  • Table 3 Diagnostics Market Opportunity for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 4 Diagnostics Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 5 PCR Cycle and Corresponding No. of Target Copies Produced
  • Table 6 PCR Testing Market Opportunity for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 7 Antibody Testing Market Opportunity Assessment for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 8 Therapy Market Opportunity Assessment for COVID-19, by Product Type, 2019-2025 ($Million)
  • Table 9 Therapy Market Opportunity Assessment for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 10 Key Vaccine Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 11 Vaccines Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 12 Immunotherapy Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 13 Immunotherapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 14 Antiviral Pipeline For COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 15 Antiviral Market Opportunity for Covid-19, by Geography, 2021-2025 ($Million)
  • Table 16 Cell-Based Therapy Pipeline for COVID-19 (Non-Exhaustive, As of May 05, 2020)
  • Table 17 Cell Based Therapy Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 18 Plasma Therapies in Pipeline for COVID-19
  • Table 19 COVID-19 Devices Platforms in Pipeline
  • Table 20 Other Therapies Market Opportunity for COVID-19, by Geography, 2021-2025 ($Million)
  • Table 21 Life Sciences Products Market for COVID-19, by Geography, 2019-2025 ($Million)
  • Table 22 COVID-19 Treatment Investments, by BARDA (U.S.)
  • Table 23 North America: COVID-19 Health & Life Sciences Market Opportunity, 2019-2025 ($Million)
  • Table 24 North America: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 25 North America: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 26 Key Economic Indicators: Europe (2019 - 2021)
  • Table 27 Europe: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 28 Europe: COVID-19 Diagnostics Market Opportunity, 2019-2025 ($Million)
  • Table 29 Europe: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 30 Key Economic Indicators: Asia (2019 - 2021)
  • Table 31 APAC: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 32 APAC: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 33 APAC: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)
  • Table 34 RoW: Health & Life Sciences Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 35 RoW: Diagnostics Market Opportunity for COVID-19, 2019-2025 ($Million)
  • Table 36 RoW: Therapy Market Opportunity for COVID-19, by Product Type, 2021-2025 ($Million)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 3 Market Size Estimation Methodology: Top-Down Approach
  • Figure 4 Research Design
  • Figure 5 Data Triangulation Methodology
  • Figure 6 Global Coronavirus Cases, As of 15 May 2020
  • Figure 7 GDP Trend Across the U.S., U.K., Germany, China, and India (2019, 2020 (F), and 2021 (F))
  • Figure 8 COVID-19 Treatment Pipeline, by Development Stage (As of May 2020)
  • Figure 9 Life Sciences Market Segmentation Impacted by Covid-19
  • Figure 10 COVID-19 Treatment Pipeline in Development, by type and Development Stage
  • Figure 11 Vaccine Pipeline, by Category & Development Stage
  • Figure 12 Immunotherapy / Antibodies Pipeline, by Development Stage (As of May 2020)
  • Figure 13 Antiviral Pipeline, by Development Stage (As of May 2020)
  • Figure 14 Cell-Based Therapy Pipeline, by Development Stage (As of May 2020)
  • Figure 15 Key Economic Indicators: U.S. (2018 To April 2020 & Forecast to 2021)
  • Figure 16 Key Growth Strategies, by Development & by Company, Feb - May 2020
  • Figure 17 Key Firms Active in COVID-19 Product Development